Skip to main content

Table 2 Treatment outcome at month 6 and 12 in relation to the nucleoside analogue used

From: A viral genome wide association study and genotypic resistance testing in patients failing first line antiretroviral therapy in the first large countrywide Ethiopian HIV cohort

Time point All: n (%) Tenofovir Zidovudine d4T p-value
Baselinea 874 467/874; 53.4% 362/874; 41.4% 44/874; 5.0%) NA
Month 6b 743/874; 85.1% 391/467; 83.7% 313/362; 86.5% 39/44; 88.6% 0.591
with VL; still on treatment 676/743; 91.0% 350/391; 89.5% 288/313; 92.0% 38/39; 97.4% 0.225
VL > 150c 90/676; 13.3% 52/350; 15.0% 34/288; 11.8% 4/38; 10.5% 0.956
VL > 1000c 57/676; 8.4% 34/350; 9.7% 19/288; 6.6% 4/38; 10.5% 0.957
Died or LTFU 131/874; 15.0% 77/426; 18.1% 49/337; 14.5% 5/38; 13.2% 0.912
Died or LTFU + VL > 150c 221/807; 27.4% 129/426; 30.2% 83/337; 24.6% 9/43; 20.9% 0.731
Died or LTFU + VL > 1000c 188/807; 23.3% 111/426; 26.0% 68/337; 20.2% 9/43; 20.9% 0.773
Month 12b 690/874; 78.9% 364/467 77.9% 289/362; 79.8% 37/44; 84.1% 0.730
with VL; still on treatment 459/690; 66.5% 219/364; 60.2% 207/289; 71.6% 33/37; 89.2% 0.006
VL > 150# 61/459; 13.3% 30/219; 13.7% 27/207; 13.0% 4/33; 12.1% 1.000
VL > 1000c 34/459; 7.4% 19/219; 8.7% 13/207; 6.3% 2/33; 6.1% 0.989
Died or LTFU 184/874; 21.1% 103/322; 32.0% 73/280; 26.1% 7/40; 17.5% 0.654
Died or LTFU + VL > 150c 245/643; 38.1% 133/322; 41.3% 100/280; 35.7% 11/40; 27.5% 0.623
Died or LTFU + VL > 1000c 218/643; 33.9% 122/322; 37.9% 86/280; 30.7% 9/40; 22.5% 0.550
  1. aone additional patient was given abacavir; bstill remaining in the study at month 6 or 12; cAlthough 67 patients continued receiving their treatment (TDF: 41, ZDV: 25, and d4T:1) during the first 6 months follow up period, they were excluded from analyses due to lack of viral load data. Hence, in the ITT analysis 426, 337, and 43 TDF-, ZDV-, and d4T-treated patients were considered, respectively. Similarly, 231 patients were receiving their treatment (TDF: 145, ZDV: 82, and d4T:4) during the 12 months follow up period, but they were excluded from the analysis due to lack of viral load data. Hence, in the ITT analysis 322, 280, and 40 TDF-, ZDV-, and d4T-treated patients were considered, respectively